Wnat to win a free spot in the '49 Bowman set break? I'm giving 1 away! To enter for a chance to win, 1) follow, 2) repost, and 3) reply, letting me know which '49 Bowman card is your favorite! #tradingcards#sportscards
🚨🚨FREE GIVEAWAY ALERT🚨🚨
2025 has been another great year and to say thank you, I'll be giving away these 3 cards on New Year’s Eve!
I'll randomly select 3 followers who LIKE, FOLLOW and RETWEET/REPOST this tweet. A HUGE thank you to everyone that has purchased or consigned this year with me and put your trust in what I do! Looking forward to another stellar year in 2026!! Drawing cutoff will be noon central on the 31st with the winners drawn by 3pm! Good luck!!
Terrific to see this message outside our office in Collegeville, PA. I’m sure it brought #joy to our colleagues there. Thanks for being a great neighbor @DowNewsroom@JimFitterling
Amazing moment at @Pfizer’s Kalamazoo plant today. #PfizerProud
The Pfizer-BioNTech #COVID19 vaccine has not been approved or licensed by the US FDA but has been authorized for emergency use to prevent COVID-19 in individuals 16+. See conditions of use: https://t.co/ENvj6P2vv2
UPDATE: The @MHRAgovuk issued a temporary authorization for emergency use of our #COVID19 vaccine with @BioNTech_Group in the United Kingdom.
This marks the first authorization of a vaccine to help fight the pandemic following a worldwide trial.
248 long days and nights
150 active clinical trial sites
43,661 courageous volunteers
Thousands of dedicated @Pfizer and @BioNTech_Group colleagues
And the hopes of billions
All leading to 1 historic moment
#PfizerProud of our FDA Submission today: https://t.co/uyo6XfGSOO
#COVID19 UPDATE: We will submit a request today to the @US_FDA for Emergency Use Authorization (EUA) of our mRNA vaccine candidate with @BioNTech_Group.
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.
UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.
Pfizer is committed to ensuring expanded #globalaccess to diagnostics, therapeutics, and vaccines that will help accelerate the end of the #COVID19 pandemic. #InnovateForAll https://t.co/RmdJADcxoS
Thank you to the 30,000 participants who have enrolled in our COVID-19 vaccine clinical trial. Your participation will make a difference for those who have been and will be impacted by COVID-19.